Epidemiology and outcomes of hospitalized patients with lung cancer and acute respiratory failure: National inpatient database analysis.

Martina Tripcovici, Aditya Sharma, Brittni J Clopton, Daniel Kurtz, Ayman O Soubani
{"title":"Epidemiology and outcomes of hospitalized patients with lung cancer and acute respiratory failure: National inpatient database analysis.","authors":"Martina Tripcovici, Aditya Sharma, Brittni J Clopton, Daniel Kurtz, Ayman O Soubani","doi":"10.4103/hemoncstem.HEMONCSTEM-D-25-00025","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute respiratory failure (ARF) is common in lung cancer patients and could be related to tumor progression, effects of treatment, or comorbid illnesses. Data on the short-term outcomes of these patients, especially those requiring invasive mechanical ventilation (IMV), remain scarce.</p><p><strong>Methods: </strong>The National Inpatient Sample database (2016-2019) was used to identify lung cancer admissions using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. ARF and IMV subgroups within lung cancer hospitalizations were identified using ICD-10-CM codes. Baseline variables were analyzed using χ2 test for categorical data and adjusted Wald tests for continuous data. Results were reported as percentages and mean ± standard deviation.</p><p><strong>Results: </strong>We identified 581,805 (24.7%) admissions for lung cancer with ARF during the study period. All-cause inpatient mortality was six times higher in lung cancer admissions with ARF compared to the non-ARF cohort (18.50% vs. 3.19%; P < 0.001). Similarly, lung cancer admissions with ARF that required IMV had significantly higher mortality compared to the cohort that did not require IMV (44.86% vs. 12.59%; P < 0.001). Lung cancer admissions with ARF requiring IMV had longer stay in the hospital (11.19 vs. 6.69 days; P < 0.001). The total hospitalization cost was more than two times higher for lung cancer admissions with ARF requiring IMV ($40,024.2 vs. $16,260.5; P < 0.001).</p><p><strong>Conclusions: </strong>In this largest study to date, we provide insight into the incidence and outcomes of lung cancer admissions with ARF. Lung cancer admissions with ARF, especially those requiring IMV, were associated with worse outcomes, longer hospital stays, and significantly higher healthcare costs. Compared to historical data, the outcomes in this large database have improved.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/oncology and stem cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/hemoncstem.HEMONCSTEM-D-25-00025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Acute respiratory failure (ARF) is common in lung cancer patients and could be related to tumor progression, effects of treatment, or comorbid illnesses. Data on the short-term outcomes of these patients, especially those requiring invasive mechanical ventilation (IMV), remain scarce.

Methods: The National Inpatient Sample database (2016-2019) was used to identify lung cancer admissions using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. ARF and IMV subgroups within lung cancer hospitalizations were identified using ICD-10-CM codes. Baseline variables were analyzed using χ2 test for categorical data and adjusted Wald tests for continuous data. Results were reported as percentages and mean ± standard deviation.

Results: We identified 581,805 (24.7%) admissions for lung cancer with ARF during the study period. All-cause inpatient mortality was six times higher in lung cancer admissions with ARF compared to the non-ARF cohort (18.50% vs. 3.19%; P < 0.001). Similarly, lung cancer admissions with ARF that required IMV had significantly higher mortality compared to the cohort that did not require IMV (44.86% vs. 12.59%; P < 0.001). Lung cancer admissions with ARF requiring IMV had longer stay in the hospital (11.19 vs. 6.69 days; P < 0.001). The total hospitalization cost was more than two times higher for lung cancer admissions with ARF requiring IMV ($40,024.2 vs. $16,260.5; P < 0.001).

Conclusions: In this largest study to date, we provide insight into the incidence and outcomes of lung cancer admissions with ARF. Lung cancer admissions with ARF, especially those requiring IMV, were associated with worse outcomes, longer hospital stays, and significantly higher healthcare costs. Compared to historical data, the outcomes in this large database have improved.

肺癌和急性呼吸衰竭住院患者的流行病学和结局:国家住院患者数据库分析。
背景:急性呼吸衰竭(ARF)在肺癌患者中很常见,可能与肿瘤进展、治疗效果或合并症有关。这些患者的短期预后数据,特别是那些需要有创机械通气(IMV)的患者,仍然很少。方法:采用《国际疾病分类第十版临床修改》(ICD-10-CM)代码对2016-2019年全国住院患者样本数据库进行肺癌入院患者识别。使用ICD-10-CM代码确定肺癌住院患者的ARF和IMV亚组。分类资料采用χ2检验,连续资料采用校正Wald检验,对基线变量进行分析。结果以百分比和平均值±标准差报告。结果:在研究期间,我们发现581,805例(24.7%)肺癌合并ARF入院。与非ARF组相比,ARF组肺癌住院患者的全因住院死亡率高6倍(18.50%比3.19%;P < 0.001)。同样,与不需要IMV的队列相比,需要IMV的ARF患者的死亡率明显更高(44.86% vs. 12.59%; P < 0.001)。因ARF而需要IMV治疗的肺癌患者住院时间更长(11.19天比6.69天,P < 0.001)。因ARF而需要进行IMV治疗的肺癌住院患者的总住院费用高出两倍多(40,024.2美元vs. 16,260.5美元;P < 0.001)。结论:在这项迄今为止规模最大的研究中,我们深入了解了肺癌合并ARF的发病率和预后。因ARF而入院的肺癌患者,特别是那些需要IMV的患者,与较差的预后、较长的住院时间和较高的医疗费用相关。与历史数据相比,这个大型数据库中的结果得到了改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信